Novanta Inc. filings document the company's operating results, governance matters and capital structure as an operating technology supplier to medical and advanced technology equipment manufacturers. Form 8-K reports furnish earnings releases and financial guidance updates, report board and committee changes, and disclose authorizations for common-share repurchases.
The company's filings also include capital-markets disclosures for Novanta's 6.50% tangible equity units, including underwriting arrangements, unit issuance and related registration-statement references. The definitive proxy statement covers shareholder voting matters, board governance, executive compensation, equity awards and pay-versus-performance information for the company's annual meeting process.
Novanta Inc. completed its acquisition of all outstanding limited liability company interests in Runway Buyer, LLC on July 23, 2026. The acquisition was for approximately $1.2 billion in cash, subject to customary adjustments based on cash, working capital, debt and transaction expenses. A $250.0 million milestone payment remains payable to the seller on or before January 8, 2027. The transaction’s pro forma information states an aggregate purchase price of approximately $1,450.6 million, funded through cash on hand and $616.0 million of borrowings.
A private placement closed June 11, 2026, generated approximately $300 million gross and $287.6 million net after $12.4 million of placement-agent fees and offering expenses; the net proceeds funded the acquisition. Runway Buyer reported $136.12 million in 2025 revenue and $11,462,563 in net income. Unaudited pro forma combined results report 2025 revenue of $1,116.720 million and a $7.385 million net loss; these figures are informational and not necessarily indicative of actual combined results.
Novanta Inc (NOVT) director Thomas N. Secor reported selling 663 shares of common stock on September 11, 2026 at an average price of $147.60 per share in an open market or private transaction. After this sale, he directly holds 662 shares. The transaction was carried out under a pre-established Rule 10b5-1 trading plan adopted on June 12, 2026.
NOVANTA INC (NOVT) is the issuer of common stock that director Thomas N. Secor has notified for potential resale under Rule 144. The notice covers 663 shares of common stock, originally acquired from the issuer as restricted stock vesting on January 2, 2026, as compensation. The proposed sale is through Fidelity Brokerage Services LLC on Nasdaq, with an indicated aggregate market value of $97,858.80 as of the notice dated September 11, 2026.
T. Rowe Price Associates, Inc. reported beneficial ownership of 2,222,444 shares of NOVANTA INC common stock, representing 6.2% of the class. It reported sole voting power over 2,216,715 shares and sole dispositive power over 2,222,444 shares, with no shared voting or dispositive power. T. Rowe Price Associates stated that this report should not be construed as an admission that it is the beneficial owner of these securities, and such beneficial ownership is expressly denied.
Novanta Inc. reported Q2 2026 revenue of 265,807 (in thousands of U.S. dollars), up from 241,049 (in thousands) a year earlier, with net income of 12,541 (in thousands) versus 4,497 (in thousands). Diluted earnings per share were $0.30, compared with $0.12 in Q2 2025.
For the first six months of 2026, revenue reached 523,514 (in thousands) and net income was 33,640 (in thousands). Operating cash flow increased to 116,540 (in thousands), lifting cash and cash equivalents to 718,650. The company strengthened its capital base through a private placement of 2,142,857 common shares for net proceeds of about $287.6 million and continues to use tangible equity units and term loans under its credit facilities. Novanta is executing multi‑year restructuring programs, with cumulative 2025 program costs of 18.7 million (in thousands) to date and an expected total of approximately $30.0 million, and has been repurchasing shares under its 2020 and 2025 repurchase plans.
Novanta Inc. reported strong results for the three months ended July 3, 2026, with GAAP revenue of $265.8 million, up 10.3% year-over-year and 9.3% organically. GAAP net income was $12.5 million and diluted EPS was $0.30, compared with $4.5 million and $0.12 a year earlier.
Non-GAAP performance also improved, with Adjusted Operating Income of $47.5 million, Adjusted EBITDA of $60.7 million (a 16.4% increase and 22.8% margin), and Adjusted Diluted EPS of $0.89, up 17.1% from $0.76. Operating cash flow rose to $64.9 million from $15.1 million, and year‑to‑date operating cash flow reached $116.5 million.
Novanta recently closed the acquisition of Riverpoint Medical, which it expects to be immediately accretive to revenue growth, gross margins, EBITDA margins, and EPS, roughly doubling recurring medical consumables to about 25% of sales and increasing medical end‑market exposure to about 60% of revenue. For full year 2026, the company guides to GAAP revenue of $1,130–$1,140 million, Adjusted EBITDA of $273–$278 million, and Adjusted Diluted EPS of $3.68–$3.74.
BlackRock, Inc. filed an amended Schedule 13G reporting a significant ownership position in NOVANTA INC common stock. BlackRock reported beneficial ownership of 4,822,354 shares, representing 13.5% of the outstanding common stock.
BlackRock reported sole voting power over 4,720,199 shares and sole dispositive power over 4,822,354 shares, with no shared voting or dispositive power. Various underlying clients and investors may receive dividends or sale proceeds, but no single such person holds more than five percent of Novanta’s outstanding common shares.
Novanta Inc. completed the acquisition of Riverpoint Medical by purchasing all equity of Runway Buyer on July 23, 2026. Buyer parties paid approximately $1.2 billion in cash at closing, plus a potential $250.0 million milestone payment due on or before January 8, 2027.
To fund the deal, an indirect subsidiary borrowed $616.0 million under its revolving and delayed draw term loan facilities, with the remainder from cash on hand, bringing consolidated debt to $854.7 million. The credit facilities mature in June 2030 and may be repaid early without penalty. Novanta states the acquisition is expected to roughly double recurring medical consumables revenue to $300 million, increase medical end-market exposure to 60% of total revenue, be immediately accretive to organic growth, margins, adjusted EBITDA and cash flows, and add $0.18–$0.25 of adjusted EPS in 2027.
Novanta Inc. Chief Executive Officer Matthijs Glastra reported open-market sales of 6,500 shares of Novanta common stock. The transactions occurred on July 2, 2026 across five trades at reported prices between $160.13 and $164.20 per share, classified as open-market sales.
The filing states these sales were effected under a pre-established Rule 10b5-1 trading plan adopted on September 11, 2025 through a trust for which his spouse is a trustee. Following the transactions, Glastra holds 29,761 shares directly and 54,382 shares indirectly through the Matthijs Glastra 2021 Irrevocable Trust.
Novanta, Inc. notice of proposed sales of Common Stock by affiliates under Form 144. The excerpt lists recent restricted stock unit grants and multiple reported sales by Matthijs Glastra in the past three months, including 7,500 shares on 05/12/2026.